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Abstract 
Background 
Lung cancer screening can reduce lung cancer mortality by 20%.  Screen-detected abnormalities may 
provide teachable moments for smoking cessation. This study assesses impact of pulmonary nodule 
detection on smoking behaviours within the first UK trial of a novel auto-antibody test, followed by 
chest x-ray and serial CT scanning for early detection of lung cancer (Early Cancer Detection Test-Lung 
Cancer Scotland Study). 
 
Methods 
Test-positive participants completed questionnaires on smoking behaviours at baseline, 1, 3 and 
6 months. Logistic regression compared outcomes between nodule (n=95) and normal CT groups 
(n=174) at 3 and 6 months follow-up.  
 
Results 
No significant differences were found between the nodule and normal CT groups for any smoking 
behaviours and odds ratios comparing the nodule and normal CT groups did not vary significantly 
between 3 and 6 months. There was some evidence the nodule group were more likely to report 
significant others wanted them to stop smoking than the normal CT group (OR across 3 and 6 month 
time points: 3.04, 95%CI 0.95, 9.73; p=0.06).     
 
Conclusion 
Pulmonary nodule detection during lung cancer screening has little impact on smoking behaviours.   
Further work should explore whether lung cancer screening can impact on perceived social pressure 
and promote smoking cessation. 
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Introduction 
Lung cancer is the most common cause of cancer-related death, with approximately 1.59 million 
deaths worldwide in 2012.1  Despite 1-year survival in England improving from 17% in 1990 to 29% 
and 33% for men and women respectively in 2010,2 mortality remains high, with a 5-year survival rate 
in England and Wales of only 9.5%.1 In Scotland, both lung cancer incidence and mortality are 
significantly higher than those for England, Wales and Northern Ireland.1 
 
Lung cancer mortality could be reduced with screening. The National Lung Cancer Screening Trial 
(NLST) showed serial computed tomography (CT) scanning reduced lung cancer mortality by 20%. 3  
However, before introduction of screening programmes, it is necessary to ensure that the overall 
benefits outweigh the harms.4  Pulmonary nodules, an incidental finding, are an example of a potential 
harm 5 and were found in 25% of screened individuals in the NLST.3  Pulmonary nodules are widely 
defined as lesions in the lung less than 3cm in diameter that are entirely surrounded by normal lung 
tissue.6, 7  Depending on size and patient history they are regularly monitored for changes for 1-5 
years.8  As a result, individuals found to have pulmonary nodules may perceive that regular 
surveillance means that smoking cessation is not necessary, reducing motivations to quit.9 Concern 
has also been expressed that those with normal CT scans may interpret this as a “licence to smoke”.10 
As the majority (85-90%) of lung cancer is attributable to smoking and lung cancer risk reduces 
substantially (by 80-90%) after smoking is stopped for more than 15 years11, it is important to assess 
the impact of CT findings from lung cancer screening on smoking behaviour.  Several lung cancer 
screening studies from outside the UK have shown that individuals with an abnormal CT scan 
(including pulmonary nodules) are more likely to remain abstinent from smoking or stop smoking than 
those with a normal CT scan.10, 12-17 More recently, the UK Lung Cancer Screening Trial (UKLS) reported 
no significant effect of needing additional investigations following an abnormal CT result on smoking 
cessation compared to those with a negative CT result in the short term (approximately 2 weeks 
following CT result). However, those needing additional investigations were significantly more likely 
to have stopped smoking up to 2 years later than those with a negative CT result. 18 
 
The Early Cancer Detection Test – Lung Cancer Scotland Study (ECLS Study)19  is evaluating use of a 
novel auto-antibody test20 as a method of case finding in lung cancer screening. This differs from 
previous lung cancer screening studies, as only those with a positive auto-antibody test receive CT 
scanning. Our study assesses the short and medium-term impact on self-reported smoking behaviour, 
intentions, confidence in stopping smoking, motivation, perceived health benefits and social pressure 
to stop smoking amongst auto-antibody test positive participants in the ECLS study, comparing those 
who were and those who were not found to have pulmonary nodules on their first CT scan.  
  
  
Methods 
The ECLS study is a randomised controlled trial assessing the effectiveness of a blood test, measuring 
autoantibodies against seven antigens (Early CDT®-Lung test) as a technique for lung cancer 
screening.19, 20  Individuals from Greater Glasgow and Clyde or Tayside NHS board areas were invited 
to participate in the study if they were aged 50-75 years with a minimum of a 20 pack-year smoking 
history (current and ex-smokers) or those with fewer pack-years and a first degree relative with lung 
cancer.  Participants completed a baseline questionnaire prior to randomisation to an Early CDT®-Lung 
test group or a non-screened control group.  Those with positive Early CDT®-Lung tests were given 
verbal and written information explaining the subsequent investigations; a chest x-ray and CT scan, 
followed by 6-monthly CT scans for 2 years.  The potential for finding a pulmonary nodule on their CT 
scan was also explained.  The majority of CT scan results were provided in writing, with a small number 
given verbally. 
 
ECLS study participants who consented to be contacted were invited to participate in a sub-study, 
assessing psychological and behavioural responses to lung cancer screening.  Additional 
questionnaires were completed at 1, 3, 6 and 12 months by those in the control and Early CDT®-
negative groups and at 1, 3, 6, 12, 18 and 24 months in the Early CDT®-positive group.  Responders to 
questionnaires were sent a £5 gift voucher. Non-responders were given postal and telephone 
reminders.  This paper presents analyses of outcomes in relation to smoking behaviours (short and 
medium-term impact on self-reported smoking behaviour, intentions, confidence in stopping 
smoking, motivation, perceived health benefits and social pressure to stop smoking) from participants 
in the Early CDT®-positive group who completed baseline and at least one follow-up questionnaire at 
3 or 6 months, and had a CT scan within the first three months of the study.  1 month follow-up data 
was not used in these analyses as most participants had not received their CT scan results at this time 
point. Those with pulmonary nodule(s) ≤ 8 mm in diameter on their first CT scan were categorised as 
being in the nodule group and those with a normal CT (this includes those with previously known 
stable pathology) were categorised as being in the normal CT group.  Those diagnosed with lung 
cancer, those withdrawing from the study, those with CT findings other than normal or nodule(s) 
≤8mm in diameter and those not responding to ≥2 consecutive follow-up questionnaires were 
ineligible for the current study. 
  
Data collection 
Participant baseline demographics including age, gender, smoking history, ethnic group, marital 
status, postcode, age at leaving full time education, employment status, family history of lung cancer 
(first-degree relative) and antidepressant medication use was collected at trial recruitment between 
December 2013 and April 2015. Baseline data was collected prior to receiving the Early CDT®-Lung test 
result. A number of questions were used to determine smoking behaviours for those participants who 
had smoked cigarettes or tobacco during the previous week.  Supplementary Table I summarises the 
data collected. 
 
Analysis 
Data analysis was undertaken using Stata Statistical Software version 13.1.21  Continuous baseline 
characteristics were non-normally distributed and are described using medians and interquartile 
ranges (IQR).  Frequencies and percentages were used to describe categorical data.  Baseline data for 
the normal CT and nodule groups was compared using chi-squared tests and Mann-Whitney U tests 
for categorical and continuous variables respectively.  Fisher’s exact test was used where expected 
numbers were small. 
 
Logistic regression models, with standard errors adjusted to account for multiple responses per 
participant, were used to compare smoking behaviours between the normal CT and nodule groups. 
Group by time interaction terms were added to models to assess whether any differences between 
the nodule and normal CT groups varied between 3 and 6 months, with a p-value of <0.01 taken as 
significant. Where there were no significant differences over time, a single odds ratio was presented 
across all follow-up time points. The number of cigarettes smoked per day was the only continuous 
outcome. Model checking indicated residual values were not normally distributed with constant 
variance. Assumptions were still not met using a logarithmic transformation, hence the number of 
cigarettes smoked per day was dichotomised into <median or ≥median and analysed using logistic 
regression as described above. In the main analysis, models were adjusted for baseline values of the 
outcome variable. In addition, models were also adjusted for study centre, age group (50-54, 55-59, 
60-64, 65-69, 70-74 years), and sex as these were the minimisation variables for randomisation to 
Early CDT®-Lung test  or no-test group in the ECLS trial.   
  
Results 
Supplementary figure 1 outlines the flow of participants through the study. In total, 338 test-positive 
ECLS trial participants took part in the smoking behaviour study.  Of these 269 (174 in the normal CT 
group and 95 in the nodule group) were eligible to be included in the analyses presented in this paper.  
Completion rates for follow-up questionnaires were 95% at 3 months and 94% at 6 months.  The 
baseline demographics of the participants by nodule status are shown in Table I.  There were no 
statistically significant differences between the two groups. 
 
 
Table II shows baseline smoking behaviours. No significant differences were seen for any of the 
behaviours between the two groups.   Smoking behaviours at 3 and 6 months are shown in Table III. 
Of note, the proportion smoking in the last week or in the period since the preceding questionnaire 
were lower at both follow-up time points than at baseline with similar reductions in the nodule and 
normal CT group (e.g. 58% and 56% smoking in the last week in the nodule and normal CT groups 
respectively at baseline compared to 47% and 46% at 3 months and 47% and 44% at 6 months 
respectively). Other smoking behaviours also appeared stable between 3 and 6 months in both the 
nodule and normal CT groups. There were few differences between the nodule and normal CT groups 
at 3 or 6 months for most smoking behaviours. At both 3 and 6 months, a higher proportion of nodule 
group participants smoked within thirty minutes of waking and were certain they could give up 
smoking for good and a lower proportion were trying to stop smoking than those in the normal CT 
group. However the differences between the nodule and normal CT group were of a similar magnitude 
to those at baseline (table II).  
 
Table IV shows odds ratios across both follow-up time points, adjusted for baseline values, comparing 
the nodule to the normal CT group.  There were no significant differences in any smoking behaviours 
between the nodule and normal CT groups across both follow-up time points and odds ratios 
comparing the nodule and normal CT groups did not vary significantly between 3 and 6 months.. There 
was some evidence that the nodule group were more likely to report significant others wanted them 
to stop smoking than the normal CT group (OR across 3 and 6 month time points: 3.04, 95%CI 0.95, 
9.73; p=0.06).   Adjusting models for study centre, age group and sex made little difference to the 
findings (supplementary table II). 
 
Discussion 
Main study findings 
This study found being diagnosed with pulmonary nodules following lung cancer screening with a 
positive Early CDT®-test and a CT scan appeared to have little impact on smoking behaviour, 
intentions, confidence in stopping smoking, motivation or perceived health benefits. Being diagnosed 
with pulmonary nodules may impact on social pressure to stop smoking as there was some evidence 
that those with pulmonary nodules were more likely to report that significant others wanted them to 
stop compared to the normal CT group.   
 
What is already known on this topic? 
 A small number of studies have explored smoking behaviour of individuals diagnosed with pulmonary 
nodules during lung cancer screening.  A systematic review in 201422 reported findings from five 
studies,10, 12, 13, 23, 24 with three studies finding significantly higher abstinence rates amongst those with 
CT results that were concerning, but not diagnostic for lung cancer, than in those whose scan results 
were not concerning for lung cancer.12, 13, 23 They also found that a higher number of abnormal CT 
results may be associated with higher abstinence rates. 22 However, two studies failed to find a 
significant difference between those with and without abnormal CT results,10, 24 and our findings are 
consistent with these. A more recent UK study also found those needing additional investigations were 
significantly more likely to stop smoking up to 2 years after screening than the control group or the 
screen negative group.18 Studies showing higher abstinence rates in those with abnormal CT results12, 
13, 18, 23 had similar study populations to ours, but had longer follow-up periods or a greater number of 
screening rounds and most had lower follow-up rates. 12, 18, 23 These studies also used different 
measures of smoking behaviour than in our study. These differences may account for variation in 
findings between these studies and our study. Our finding that smoking behaviours appeared stable 
over time in the normal CT group suggests a normal result is not being interpreted by participants as 
a “licence to smoke”. This is consistent with findings from several previous studies.10, 14, 18 
 
Why might a positive Early CDT®-test coupled with pulmonary nodules on CT scan have little impact 
on smoking behaviour? Both groups showed reductions in smoking prevalence at 3 and 6 months 
compared to baseline so the positive EarlyCDT-Lung test may have had a greater impact on smoking 
than the finding of pulmonary nodules on CT scans. One potential explanation is  that those in the 
nodule group may have been provided with a degree of reassurance because they may have  perceived 
their nodules as a reason for having a positive Early CDT®-Lung test.  This is supported by a qualitative 
study from America, which found individuals diagnosed with nodules felt that this meant that 
screening was working, that lung nodules represented lung cancer found so early that it was harmless 
at that point in time and that repeated scans would indicate when it was time to stop smoking, for 
example, when changes were seen on future imaging.9  However, it would seem that this reassurance 
may not have been felt by the friends and family of study participants as the nodule group appeared 
to be more likely to report significant others wanted them to stop than the normal CT group.  To our 
knowledge, this is a new finding in the context of lung cancer screening, and one that requires 
confirmation from other studies.  It is also possible that the impact of an abnormal CT result may be 
more apparent at later follow-up time points. The UKLS reported short and longer term follow-up, 
finding no impact on smoking cessation in the short term (2 weeks post CT result), but a significant 
impact up to 2 years later in those requiring additional investigations.18 This, coupled with the finding 
of a dose-response relationship between the number of abnormal CT scans and abstinence rates, 
suggests exploring the impact of pulmonary nodules on smoking behaviour at later time points in the 
ECLS trial may be useful.  
               
Several lung cancer screening studies have incorporated and evaluated smoking cessation 
interventions,25-28 with some positive findings, and although further research is needed in this area, 
smoking cessation interventions are recommended, at each screening round, for smokers who take 
part in lung cancer screening programmes.29  One issue to consider is whether providing smoking 
cessation support as part of a lung cancer screening programme may affect willingness to undergo 
screening.  Lung cancer screening studies, including those in the UK, have shown evidence of 
participation bias, with lower participation rates in current than ex-smokers.30-32 Lower participation 
rates amongst those at higher risk of lung cancer will impact on the effectiveness of screening 
programmes. A recent meta-synthesis of qualitative studies exploring cancer screening attendance 
decisions in the UK found screening can be perceived as an attempt to exert control over individuals, 
which individuals felt should be resisted.33  Focus groups conducted prior to the ECLS trial also found 
some individuals worried about being coerced into stopping smoking if they took part in lung cancer 
screening.34  It is possible that smokers may decline lung cancer screening because they do not want 
to stop smoking. It is therefore important that screening information addresses this issue and that 
smoking cessation provided as part of a lung cancer screening programme is delivered in a sensitive 
and non-threatening manner. 
 
What this study adds   
Detection of pulmonary nodules on a CT scan following lung cancer screening in the UK does not 
appear to impact substantially on smoking behaviour. However, receiving a positive Early CDT®-Lung 
test may have reduced smoking prevalence and this possibility will be explored in the main trial 
analysis.  If the UK implements a lung cancer screening programme, this would present an ideal 
opportunity to evaluate the impact of smoking cessation support nested within the screening 
programme.  Our findings suggest research exploring the potential for, and impact of exploiting  the 
greater perceived social pressure to quit in those with pulmonary nodules would be useful.  In 
addition, it would also be important to explore the impact of the information provided to those invited 
to screening,  the impact of providing screening  results and abnormal CT findings in the presence of 
significant others (with appropriate patient consent) and the impact of incorporating smoking 
cessation on screening uptake and whether this differs by lung cancer risk.  
 
Study limitations 
This is the first study examining the smoking behaviour following detection of pulmonary nodules on 
a chest CT scan in those with a positive Early CDT®-Lung test within a UK population.  We achieved a 
very high follow-up rate which was higher than several previous studies,12, 18, 23 used a range of 
questions to establish smoking behaviour and adjusted analyses for baseline responses.  Our study 
sample comprised those with positive Early CDT®-Lung test results in the main trial and a post-hoc 
power calculation indicates it provided 80% power at the 5% significance level to detect a difference 
at 3 months follow-up of 18% in the proportion reporting smoking in the last month (i.e. 40% in the 
nodule group and 58% in the normal CT group; equivalent to 31% of smokers stopping smoking). This 
is similar to quit rates in those with abnormal CT results from several other studies; 62% in the study 
by Ostroff10, 42% in the study by Townsend,12 30% in the UKLS pilot study18 and 26% in the study by 
Styn,13 but higher than quit rates in the Danish LCST (18%)23 and the NELSON trial (12%).24 Our study 
therefore may not have had adequate power to detect small, but potentially clinically important 
differences in smoking outcomes.  Also, as only a small proportion of participants would have received 
their CT scan result at the time of completing the 1 month questionnaires, we were unable to explore 
the immediate impact of pulmonary nodule detection on smoking outcomes.   
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Table I. Demographic characteristics at baseline amongst participants in the nodule group and those in the normal 
CT group (% indicates column percentage unless otherwise stated) 
Characteristics 
Nodule 
n = 95 (%) 
Normal CT 
n = 174 (%) 
Statistical Test 
Study Centre 
Glasgow 
Tayside 
 
72 (75.8) 
23 (24.2) 
 
123 (70.7) 
51 (29.3) 
 
χ²(1) = 0.80, p = 0.37 
 
Age (years - median (IQR*))  
50-54 years 
55-59 years 
60-64 years 
65-69 years 
70-74 years 
75-79 years 
61 (56, 67) 
17 (17.9) 
22 (23.2) 
21 (22.1) 
23 (24.2) 
12 (12.6) 
0 (0) 
60 (55, 66) 
37 (21.3) 
48 (27.6) 
31 (17.8) 
40 (23.0) 
15 (8.6) 
3 (1.7) 
z = -1.30, p = 0.19 
χ²(5) = 4.06, p = 0.54 
  
  
  
  
  
Gender 
Male 
Female 
  
39 (41.1) 
56 (58.9) 
  
80 (46.0) 
94 (54.0) 
  
χ²(1) = 0.60, p = 0.44 
  
Smoking Status 
Current smoker 
Ex-smoker  
  
50 (52.6) 
45 (47.4) 
  
88 (50.6) 
86 (49.4) 
  
χ²(1) = 0.10, p = 0.75 
  
Smoking Pack-year (median (IQR)) 35 (26, 48) 32.5 (25, 49) z = -0.83, p = 0.41 
Ethnic Origin 
White British 
Other  
 
93 (97.9) 
 2 (2.1) 
[4] 
165 (97.1) 
5 (2.9) 
  
Fisher's exact test 
p = 1.00 
Marital Status 
Single 
In a relationship/married/civil partnership 
Widowed 
Separated/divorced 
 
5 (5.3) 
67 (70.5) 
10 (10.5) 
13 (13.7) 
[5] 
15 (8.9) 
103 (61.0) 
17 (10.0) 
34 (20.1) 
  
χ²(3) = 3.34, p = 0.34 
  
  
  
Scottish Index of Multiple Deprivation (Rank) 
1-1395 (most deprived) 
1396-2790 
2791-4186 
4187-5581 
5582-6976 (least deprived) 
  
35 (36.8) 
27 (28.4) 
14 (14.7) 
8 (8.4) 
11 (11.6) 
  
68 (39.1) 
42 (24.1) 
27 (15.5) 
23 (13.2) 
14 (8.1) 
  
χ²(4) = 2.60, p = 0.63 
  
  
  
  
Prescribed medication for low mood 
Yes 
No 
[1] 
11 (11.7) 
83 (88.3) 
[4] 
30 (17.7) 
140 (88.3) 
  
χ²(1) = 1.63, p = 0.20 
  
Age at leaving full-time education  
(years - median (IQR))  
[2] 
16 (15, 16) 
[7] 
16 (15, 16) 
  
z = 0.29, p = 0.77 
Work Status 
Employed 
Unemployed  
Retired/other 
 
40 (42.1) 
16 (16.8) 
39 (41.1) 
[5] 
75 (44.4) 
33 (19.5) 
61 (36.1) 
  
χ²(2) = 0.70, p = 0.70 
  
  
First degree relative with lung cancer 
No 
Yes 
  
70 (73.7) 
25 (26.3) 
  
115 (66.1) 
59 (33.9) 
  
χ²(1) = 1.65, p = 0.20 
  
*Interquartile range. [Missing values] 
 
Table II. Smoking behaviour at baseline amongst participants in the nodule group and those in the 
normal CT group (column percentage unless otherwise stated) 
Smoking Behaviour  
Nodule 
n = 95 (%) 
Normal CT 
n = 174 (%) 
Statistical Test 
Not counting the last week, has smoked in 
the last month 
Yes 
No 
  
[9] 
54 (62.8) 
32 (37.2) 
  
[19] 
90 (58.1) 
65 (41.9) 
  
  
χ²(1) = 0.51, p = 0.47 
  
Has smoked in the last week 
Yes 
No 
Smokes <30 minutes after waking 
No 
Yes 
Number of cigarettes smoked/day  
Median (IQR) 
[9] 
50 (58.1) 
36 (41.9) 
[1] 
11 (22.5) 
38 (77.6) 
 
20 (15, 25) 
[19] 
86 (55.5) 
69 (44.5) 
[2] 
30 (35.7) 
54 (64.3) 
[1] 
15 (10, 25) 
  
χ²(1) = 0.16, p = 0.69 
  
  
χ²(1) = 2.55, p = 0.11 
  
  
z = -1.85, p = 0.07 
Intends to give up smoking in next four 
weeks 
Yes 
No / Don't know 
17 (34.0) 
33 (66.0) 
[4] 
18 (22.0) 
64 (78.0) 
  
χ²(1) = 2.31, p = 0.13 
  
Confident could give up smoking for good 
Certain 
Not certain / Don't know 
12 (24.0) 
38 (76.0) 
[4] 
10 (12.2) 
72 (87.8) 
  
χ²(1) = 3.12, p = 0.08 
  
Continue smoking 
I would like to keep smoking / Don't 
know if I want to stop 
I would like to stop smoking 
 
16 (32.0) 
34 (68.0) 
[4] 
34 (41.5) 
48 (58.5) 
  
χ²(1) = 1.18, p = 0.28 
  
Thinking about stopping smoking 
Not thinking about/trying to stop  
Thinking about or trying to stop  
 
27 (54.0) 
23 (46.0) 
[4] 
31 (37.8) 
51 (62.2) 
  
χ²(1) = 3.31, p = 0.07 
  
Thinks health will improve if stops smoking 
Disagree /Don't know 
Agree  
9 (18.0) 
41 (82.0) 
[4] 
11 (13.4) 
71 (86.6) 
  
χ²(1) = 0.51, p = 0.48 
  
People important to participant want them 
to stop smoking 
Disagree /Don't know 
Agree 
 
8 (16.0) 
42 (84.0) 
[4] 
13 (15.9) 
69 (84.1) 
  
χ²(1) = 0.0005, p = 0.98 
  
Tried to cut down in the last month 
Yes 
No 
Tried to stop in the last month 
Yes 
No 
[2] 
33 (68.8) 
15 (31.3) 
 
13 (26.0) 
37 (74.0) 
[5] 
54 (66.7) 
27 (33.3) 
[5] 
25 (30.9) 
56 (69.1) 
  
χ²(1) = 0.06, p = 0.81 
  
  
χ²(1) = 0.36, p = 0.55 
  
[Missing values] 
 
Table III. Smoking behaviour at 3 and 6 months amongst participants in the nodule group and those in the normal CT group (column percentage unless otherwise stated) 
Smoking Behaviour 
3 months 6 months 
Nodule Normal CT Nodule Normal CT 
n = 91 (%) n = 165 (%) n = 91 (%) n = 163 (%) 
        
Not counting the last week has smoked in the last 2 months/3 months*     
Yes  45 (49.5) 75 (45.5) 44 (48.4) 77 (47.5) 
No  46 (50.5) 90 (54.5) 47 (51.7) 85 (52.5) 
Has smoked in the last week    [1] 
Yes 43 (47.3) 76 (46.1) 43 (47.3) 71 (43.8) 
No 48 (52.7) 89 (53.9) 48 (52.7) 91 (56.2) 
Smokes <30 minutes after waking     
No 12 (27.9) 32 (42.1) 13 (30.2) 28 (39.4) 
Yes 31 (72.1) 44 (57.9) 30 (69.8) 43 (60.6) 
Average number of cigarettes smoked/day  [1]   
Below median  
Median or above 
21 (48.8) 
22 (51.2) 
40 (53.3) 
35 (46.7) 
20 (46.5) 
23 (53.5) 
38 (53.5) 
33 (46.5) 
Intends to give up smoking in the next four weeks    [1] 
Yes 14 (32.6) 21 (27.6) 15 (34.9) 20 (28.6) 
No/Don't know 29 (67.4) 55 (72.4) 28 (65.1) 50 (71.4) 
Confident could give up smoking for good     
Certain 13 (30.2) 12 (15.8) 9 (20.9) 11 (15.5) 
Not certain/Don't know 30 (69.8) 64 (84.2) 34 (79.1) 60 (84.5) 
Continue smoking  [1]   
I would like to keep smoking/Don't know if I want to stop 17 (39.5) 34 (45.3) 18 (41.9) 29 (40.9) 
I would like to stop smoking  26 (60.5) 41 (54.7) 25 (58.1) 42 (59.2) 
Thinking about/trying to stop smoking  [1]  [1] 
Not trying/thinking about stopping 22 (51.2) 32 (42.7) 23 (53.5) 23 (32.9) 
Trying/thinking about stopping smoking 21 (48.8) 43 (57.3) 20 (46.5) 47 (67.1) 
Thinks health will improve if stops smoking     
Disagree/Don't know 7 (16.3) 15 (19.7) 9 (20.9) 13 (18.3) 
Agree 36 (83.7) 61 (80.3) 34 (79.1) 58 (81.7) 
People important to participant want them to stop smoking     
Disagree/Don't know 5 (11.6) 15 (19.7) 5 (11.6) 17 (23.9) 
Agree 38 (88.4) 61 (80.3) 38 (88.4) 54 (76.1) 
Tried to cut down in the last 2 months/3 months*     
Yes 30 (69.8) 49 (64.5) 23 (53.5) 49 (69.0) 
No  13 (32.8) 27 (35.5) 20 (46.5) 22 (31.0) 
Tried to stop in the last 2 months/3 months*     
Yes 13 (30.2) 22 (29.0) 9 (20.9) 17 (23.9) 
No 30 (69.8) 54 (71.0) 34 (79.1) 54 (76.1) 
*Reporting time period was since last questionnaire, i.e. 2 months reporting period at 3 months follow-up and 3 months reporting period at 6 months follow-up. [Missing values] 
Table IV.  Odds ratios for smoking behaviour variables during 3 to 6 months follow-up, adjusted for baseline value, comparing participants in the nodule group to those 
in the normal CT group 
Smoking behaviour  
Adjusted odds ratio             
(95 %CI)  
P-value for difference 
between odds ratios at 3 
and 6 months  
Not counting the last week, has smoked in the last 2 months/3 months* 
 
Has smoked in the last week 
 
Smokes <30 minutes after waking 
 
Smokes ≥ median number of cigarettes/day 
 
Intends to give up smoking in next four weeks 
 
Confident could give up smoking for good 
 
Would like to stop smoking 
 
Thinking about or trying to stop smoking 
 
Thinks health will improve if stops smoking 
 
People who are important to participant want them to stop smoking 
 
Tried to cut down in the last 2 months/3 months* 
 
Tried to stop in the last 2 months/3 months* 
0.81 (0.33, 2.00) 
 
1.02 (0.46, 2.30) 
 
1.02 (0.40, 2.58) 
 
1.26 (0.55, 2.90) 
 
1.48 (0.66, 3.32) 
 
1.91 (0.80, 4.58) 
 
0.98 (0.46, 2.08) 
 
0.76 (0.38, 1.54) 
 
1.16 (0.51, 2.65) 
 
3.04 (0.95, 9.73) 
 
0.82 (0.40, 1.66) 
 
1.49 (0.66, 3.39) 
0.22 
 
0.71 
 
0.42 
 
0.47 
 
0.89 
 
0.22 
 
0.21 
 
0.11 
 
0.61 
 
0.25 
 
0.06 
 
0.58 
*Reporting time period was since last questionnaire, i.e. 2 months reporting period at 3 months follow-up and 3 months reporting period at 6 months follow-up.  
     
 
